Esophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)
Conditions
Brief summary
Early metabolic response evaluation may predict clinical and histopathological response after neoadjuvant chemotherapy. Its value in neoadjuvant chemoradiotherapy (CRT) is unknown. Our aim was to assess the value of early metabolic response after one cycle of chemotherapy using 18-FDG-PET-CT to predict pathological response and outcome in cT2-4 N0/+ esophageal cancer treated by neoadjuvant CRT and esophagectomy.
Interventions
OTHER18-FDG-PET-CT
Sponsors
Universitaire Ziekenhuizen KU Leuven
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* locally advanced esophageal cancer (cT2-4 N0/+)
Exclusion criteria
* PET-CT not performed at UZLeuven * Other tumor types * Distant metastases (organ)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| early metabolic response to predict pathological response and outcome | — | assess the value of early metabolic response with 18-FDG-PET-CT (i.e. a decrease of ≥ 35% of SUVmean) after a single cycle of chemotherapy followed by neoadjuvant CRT and esophagectomy as a tool to predict pathological response and outcome in patients with cT2-4N0/+ carcinoma of the esophagus and GE-junction (GEJ). |
Secondary
| Measure | Time frame |
|---|---|
| to study correlations between early metabolic response, late metabolic response, histopathological response and outcome. | — |
Countries
Belgium
Outcome results
None listed